Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F van Rhee

Showing results (71-80 of 82) with videos related to

Pageof 9
Sort By:
Blood|September 1, 1995
Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patientsH J Kolb, A Schattenberg, J M Goldman, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 22, 2001
In vitro generation of Epstein-Barr virus-specific cytotoxic T cells in patients receiving haplo-identical allogeneic stem cell transplantationP Musk, S Szmania, A T Galloway, et al.
Leukemia|August 1, 2015
Inhibiting MEK in MAPK pathway-activated myelomaC J Heuck, Y Jethava, R Khan, et al.
Leukemia|March 11, 2015
The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myelomaX Papanikolaou, D Alapat, A Rosenthal, et al.
Leukemia|April 18, 2012
Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocolsS Z Usmani, B Nair, P Qu, et al.
Bone Marrow Transplantation|October 23, 1997
Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow TransplantationF van Rhee, R M Szydlo, J Hermans, et al.
Leukemia|October 4, 2016
Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myelomaJ R Sawyer, E Tian, J D Shaughnessy, et al.
Blood Cancer Journal|July 30, 2016
Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myelomaY Jethava, A Mitchell, M Zangari, et al.
Blood Cancer Journal|September 17, 2016
Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myelomaY Jethava, A Mitchell, M Zangari, et al.
Leukemia|December 22, 2018
Combination of flow cytometry and functional imaging for monitoring of residual disease in myelomaL Rasche, D Alapat, M Kumar, et al.
Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
Blood|September 1, 1995
Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patientsH J Kolb, A Schattenberg, J M Goldman, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 22, 2001
In vitro generation of Epstein-Barr virus-specific cytotoxic T cells in patients receiving haplo-identical allogeneic stem cell transplantationP Musk, S Szmania, A T Galloway, et al.
Leukemia|August 1, 2015
Inhibiting MEK in MAPK pathway-activated myelomaC J Heuck, Y Jethava, R Khan, et al.
Leukemia|March 11, 2015
The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myelomaX Papanikolaou, D Alapat, A Rosenthal, et al.
Leukemia|April 18, 2012
Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocolsS Z Usmani, B Nair, P Qu, et al.
Bone Marrow Transplantation|October 23, 1997
Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow TransplantationF van Rhee, R M Szydlo, J Hermans, et al.
Leukemia|October 4, 2016
Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myelomaJ R Sawyer, E Tian, J D Shaughnessy, et al.
Blood Cancer Journal|July 30, 2016
Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myelomaY Jethava, A Mitchell, M Zangari, et al.
Blood Cancer Journal|September 17, 2016
Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myelomaY Jethava, A Mitchell, M Zangari, et al.
Leukemia|December 22, 2018
Combination of flow cytometry and functional imaging for monitoring of residual disease in myelomaL Rasche, D Alapat, M Kumar, et al.
Pageof 9